Assessment of the impact of the new blister packaging of Biktarvy® (B/F/TAF) on treatment satisfaction of people living with HIV

Authors

Cruz JP^{1,2}, Santos O^{3,4}, Rodrigues M¹, Morais R¹, Borralho T¹, Ferreira F¹, Ferreira A⁵. Albuquerque J^{5,6}, Nogueira P³, Silva MP⁷, and Antunes F³

- 1. Serviços Farmacêuticos da Unidade de Saúde Local Santa Maria, Lisboa, Portugal
- 2. iMed.ULisboa Institute for Medicine Research, Faculdade de Farmácia, Universidade de Lisboa, Portugal
- 3. Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Portugal
- 4. Unbreakable Idea Research, Painho, Portugal
- 5. BlueClinical Investigação e Desenvolvimento em Saúde, Lda, Porto, Portugal
- 6. Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa, Portugal
- 7. Gilead Sciences, Lda, Lisboa, Portugal

Abstract

1

- 2 **Background:** Antiretroviral therapy (ART) is highly effective in people living with HIV
- 3 (PLHIV), but its success depends on treatment satisfaction and adherence. A determinant of
- 4 satisfaction regards how the medication is delivered to the patient, namely how it is
- 5 contained (e.g., bottles, blisters, etc). A new packaging of Biktarvy® has been introduced as
- 6 a monthly blister, aiming to improve satisfaction, facilitate traceability of daily medication,
- 7 portability, and discretion (reducing stigma associated with ART), and, ultimately, enhance
- 8 adherence.
- 9 Goals: The study's objective was to assess the impact of changing the packaging of
- 10 Biktarvy® (B/F/TAF) from a standard pill bottle to a monthly blister with a weekly calendar
- 11 on therapy satisfaction. Additionally, the association between treatment satisfaction and
- 12 selected patients' characteristics (e.g., ART duration) was evaluated. A secondary goal was
- 13 to characterize the association between the change of packaging on patient's adherence.
- 14 **Methods:** This is an observational longitudinal (retrospective and prospective) study with
- 15 patients following ART for at least six months (ambulatory clinical management) recruited
- 16 according to a non-probabilistic sequential sampling. Satisfaction was measured at two
- 17 different moments: at baseline, HIVTSOs were used to assess satisfaction within the
- 18 previous six months' use of medication containers (bottles). Six months later, patients filled
- 19 in the HIVTSQc to assess their perception of satisfaction change with the new packaging
- 20 (blister). Adherence was assessed by pharmacy medication dispensing at the hospital.
- Results: The study enrolled 105 patients in two selected centers (102 patients completed 21
- 22 the study). Patients were significantly more satisfied (HIVTSQc scores) with ART when
- 23 using the new Biktarvy® blister pack package. Importantly, gains of ART satisfaction were
- higher among those less satisfied with the bottle packaging. No significant associations 24
- 25 were found between HIVTSQc scores and sociodemographic or ART-related variables.
- 26 **Keywords**: PLHIV; Antiretroviral therapy; Patient satisfaction; Adherence

Introduction

27

28

- In the last decade, antiretroviral therapy (ART) has demonstrated high efficacy, resulting in 29
- 30 higher than 90% viral suppression rates. Therapeutic guidelines identify several regimens
- 31 that Eathorpredict products how gotern manipur excisen continued by bear deview per a phould winge weighted while infractionatice.

(PLHIV), including single tablet coformulations¹.

32

33

34

35 36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59 60 The success of ART depends on treatment satisfaction and adherence, which are impacted by several factors, including medication usage facility, patient perception of results, and side effects. These factors must be considered when making treatment decisions in the clinical management of PLHIV². For all these reasons, satisfaction has been considered relevant in the assessment and differentiation between therapeutic regimens, aiming to improve clinical outcomes, the well-being of PLHIV, and maximizing improvement of health status^{3,4}.

Medication packaging in blister packs, with a weekly calendar, has the potential to contribute to improving adherence to ART and optimizing outcomes in the treatment of PLHIV. In the scope of treatment of hypertension, patients with medication in blisters with weekly calendars renewed their prescription more frequently, had higher Medication Possession Ratio (MPR) and better control of blood pressure at 12 months⁵. Additionally, a meta-analysis of 52 studies (n = 22.858) involving patients with different diseases showed an increase in adherence from 63% to 71%, related to the change in the packaging of the medication to blisters with calendars, which demonstrates a practical improvement in treatment adherence because of this tablet package modification⁶.

Biktarvy® is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Currently, Biktarvy® new package contains the same number of units (30 tablets), but packaged in four blisters of seven tablets, with a weekly calendar, and one blister of two tablets. This new packaging has the potential for the patient to improve the adherence to therapy, facilitating the traceability of daily medication dosage, its portability and greater medication discretion, reducing the risk of stigma associated with ART. In Portugal, there was a complete replacement of units of Biktarvy® in bottles by Biktarvy® in blisters, until May 2022⁷.

This project aimed to estimate the impact of the new Biktarvy® packaging containing the same number of units (30 tablets), but packed in four blisters of seven tablets, with a weekly calendar, and one blister of two tablets, on patient's satisfaction (main outcome) and adherence (secondary outcome) with ART.

Materials and methods

Research strategies

- The study followed an observational retrospective/prospective design with PLHIV being followed in two Portuguese hospitals. Data collected referred to a period of ART of at least six months before the change of packaging (bottle; retrospective data) and six months of experience with the new packaging (blister; prospective data).
- 68 The study was conducted in accordance with the clinical study protocol (CSP), the 69 International Council for Harmonization, Good Clinical Practices, and the Declaration of 70 Helsinki, as well as the applicable European and Portuguese laws and regulations approved
- 71 by the Ethics Committee of the Centro Académico de Medicina de Lisboa (reference
- 72 number 226/22).

61 62

63 64

65

66 67

79 80

81

82

83

84

85

86

87

88 89

90 91

73 All patients signed a written informed consent form before entering the study. Each 74 participant received a full explanation of the project goals, procedures, and implied tasks 75 (and burden) from patients. Subjects were informed that their participation was voluntary 76 and assured that they could abandon the study at any time without any prejudice. They also 77 received a copy of the subject's information and, after being fully clarified, signed the 78 informed consent form.

Sampling: inclusion and exclusion criteria

- The sample size was planned to enroll 100 PLHIV (including at least 20 women) on treatment with Biktarvy®, being over 18 years old, under ambulatory clinical management in two Portuguese hospitals for at least six months and accepting to participate voluntarily in the study.
- Patients coming to the hospital pharmacy were included sequentially (non-probabilistic sampling), and the sample size was determined to allow an estimate of the patients with timely prescription delivery in the hospital pharmacy (before the time of prescription collection), with the precision of 7% to 10%. The first patient visit occurred in August 2022, and the last patient visit occurred in December 2023.

Data collection and instruments

- 92 Subjects' data was directly collected on paper-based clinical reports forms (CRFs).
- 93 Subsequently, data were transcribed into the study database by a data entry operator. Each
- 94 patient was given a study reference number, which was archived in the clinical file.
- 95 Data collected included demographic information (age, gender, nationality, level of 96 education), clinical and laboratory data (duration of ART, viral load, and CD4 T
- 97 lymphocytes count). For assessing satisfaction with ART, two instruments have been used:
- the Portuguese version of the HIV Treatment Satisfaction Questionnaires version "s" 98
- 99 (HIVTSQs), at baseline (retrospective assessment related to the previous six months), and
- 100 the Portuguese version for the HIV Treatment Satisfaction Questionnaires version "c"
- 101 (HIVTSQc), six months after starting the use of Biktarvy® monthly blisters. HIVTSQs and
- 102 HIVTSQc have been developed by Woodcock & Bradley, with evidence of sound

- 103 psychometric properties^{8,9}. The HIVTSQs is composed of 10 items being answered in a
- 104 seven-points Likert-type scale (varying from 0 = "very dissatisfied" to 6 = "very satisfied").
- 105 The HIVTSQs provides a global score of satisfaction as well as scores for two
- 106 subdimensions: the HIVTSOs General Satisfaction/Clinical subscale and the HIVTSOs
- 107 Lifestyle/Ease subscale; the HIVTSQc also includes a subscale: the HIVTSQc General
- 108 Satisfaction/Clinical subscale.
- 109 Additionally, and for a better understanding of the factors of satisfaction with ART, patients
- 110 were asked about their level of agreement with four statements, both at baseline and at
- 111 follow-up: The packaging of this medication allows me to easily check if I've taken my daily
- 112 pill, This medicine comes in a package that lets me take the pill easily and
- 113 without anyone noticing. This medicine's packaging reminds me that I need to refill my
- 114 prescription, and I don't like the way this medicine is packaged. Finally, patients reported
- 115 their level of agreement with one more statement, at the follow-up moment: I am more
- 116 satisfied with this type of medication packaging than with the previous one, which was a
- 117 plastic bottle. Level of agreement was indicated through a 5-points Likert scale ranging
- 118 from I = totally disagree to 5 = totally agree.
- 119 To assess the impact of the new Biktarvy® packaging on adherence, pharmacy medication
- 120 dispensing was measured, more specifically, by registering the number of tablets supplied
- 121 in the last delivery per number of days elapsed since the last delivery. Pharmacy medication
- 122 dispensing data were collected by pharmacy records, and questionnaires were completed
- 123 while patients waited in the hospital pharmacy (a representation of the study design is
- 124 presented in Figure 1).

125 126

127 128

Figure 1. Study design diagram

Data analysis

- 129 The statistical analyses were conducted using R statistical software version 4.2.1.
- 130 Descriptive statistics were used to analyze results: percentages and absolute frequencies to
- 131 describe the categorical variables; minimum, maximum, interquartile range, means,
- 132 medians, and standard deviation for the quantitative variables.
- 133 All ten items from HIVTSQs were summed up to obtain a treatment satisfaction score (0 to
- 134 60), where higher scores represent greater satisfaction. The HIVTSQs General Satisfaction
- 135 / Clinical subscale includes the items 1, 2, 3, 9 and 10 (range: 0 to 30), and the HIVTSQs
- 136 Lifestyle/Ease subscale includes the remaining items, namely the items 4, 5, 6, 7 and 8
- 137 (range: 0 to 30).
- 138 For the HIVTSQc, the sum of all items results in a treatment satisfaction (change) score
- 139 (range: -30 to 30), where positive values are associated with improvement in satisfaction
- 140 with treatment, the 0 score represents no change, and negative values indicate a
- 141 deterioration in treatment satisfaction. For the HIVTSQc General Satisfaction / Clinical
- 142 subscale and HIVTSQc Lifestyle/Ease subscale, the same items as in HIVTSQs subscales
- 143 were included (range: -15 to 15). Cronbach alpha was used to assess internal consistency
- 144 for both HIVTSQs and HIVTSQc, and correlations were applied to assess the convergent
- 145 validity between these two scales.
- 146 To evaluate the effect of switching the medication from a standard pill bottle to a monthly
- 147 blister in patient satisfaction, a unilateral Wilcoxon signed rank test was applied (alternative

hypothesis: pseudomedian > 0) to the score in the HIVTSQc scale and its subscales. Differences between independent samples in the distribution of these scores was tested using the Wilcoxon rank sum test. Linear regression models have been performed to assess the predictive effect of baseline satisfaction on satisfaction change. The scores for HIVTSQc scale, HIVTSQc General Satisfaction subscale, HIVTSQs Clinical subscale, e HIVTSQc Lifestyle/Ease subscale were found as very skewed (left-skewed distribution). Therefore, their values were shifted and reversed for modeling purposes, as follows: HIVTSQc scale recoded = 61 + 1 -(HIVTSOc scale + 31); HIVTSOc General Satisfaction / Clinical subscale recoded = 31 + 1 - (HIVTSOc General Satisfaction / Clinical subscale + 16); HIVTSOc Lifestyle/Ease subscale recoded = 31 + 1 - (HIVTSOc Lifestyle/Ease subscale + 16). Resulting scores were log-transformed and included in the linear regression models as dependent variables. The models included as predictors sex, age group, education, nationality, and antiretroviral therapy duration, adjusting for the treatment satisfaction score at baseline. When studying the predictive effect of treatment satisfaction at baseline (for HIVTSQs scale, HIVTSQs General Satisfaction / Clinical subscale, and HIVTSQs Lifestyle/Ease subscale) on HIVTSQc, HIVTSQc General Satisfaction / Clinical e HIVTSQc Lifestyle/Ease, simple models (no additional variables, in these equations) have been used. The predictors mentioned above were also included all-together in one model (M2). Estimates and 95%

Results

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168 169

170 171

172

173

174

175

176 177

One hundred and five PLHIV were enrolled in the study. Two were discontinued due to a physician's decision to switch ART, and one had not completed six months of using Biktarvy® in blisters by the end of the data collection process (therefore, not considered for assessing satisfaction with the blister packaging). Table 1 summarizes the demographic and clinical characteristics of participants at baseline.

Table 1. Sociodemographic and clinical characteristics of the participants

confidence intervals (CI), and p-values are presented.

Sociodemographic variables	•	•				
	n	105				
Sex, n (%)	Female, n (%)	22 (21.0)				
	Male, n (%)	83 (79.1)				
	n	105				
A	Mean	43.35				
	SD	11.69				
Age	Mediana [Q1, Q3]	42.00 (34.00, 53.00)				
	Minimum	21				
	Maximum	79				
	n	105				
	No formal education	2 (1.9)				
Scholarship level, n (%)	Primary (basic) education	27 (25.7)				
	Secondary education	37 (35.2)				
	Superior education	39 (37.1)				
Nationality n (0/)	n	105				
Nationality, n (%)	Portuguese	59 (56.20)				

	Non-Portuguese	46 (43.8)
Clinical variables		
	n	105
	Less than 1 year	2 (1.9)
Antiretroviral therapy duration, n (%)	1 - 5 years	53 (50.5)
	6 - 10 years	14 (13.3)
	More than 10 years	36 (34.3)
	n	105
HIN : 11 1 - 1 - (0/)	Not detectable	83 (79.0)
HIV viral load, n (%)	20 - 200 copies/mL	21 (20.0)
	201 - 1000 copies/mL	1 (1.0)
	n	105
CDATE 1 1 (0/)	< 350 cells/mm ³	6 (5.7)
CD4 T lymphocytes count, n (%)	351 - 500 cells/mm ³	15 (14.3)
	> 500 cells/mm³	84 (80.0)

n: number of subjects; HIV: human immunodeficiency virus

178

179 180

181

182

183

184

185

186

187

188

189

190

191 192

193

194

195

Out of the 105 participants, twenty-one (21.0%) were females. The mean age was 43.35 years (s.d:11.69; min 21, max 79 years old), 35.2% and 37.1% had secondary and superior education, respectively, and 43.8% were born outside Portugal. Only two participants had been following ART for less than one year. 79.0% had a non-detectable viral load, and 80.0% had a CD4T lymphocyte count higher than 500 cells/mm³.

The scales used for assessing satisfaction performed well psychometrically: the internal reliability coefficients for HIVTSQs and HIVTSQc were found to be good (alpha = .76 for HIVTSQs; alpha = .88 for HIVTSQc). The correlation between HIVTSQs and HIVTSQc was also significant (rho=.327) (Figure 2).

Figure 2. HIVTSQs (and subscales) and HIVTSQc total scores correlations (Spearman correlation)

As Table 2 shows, the scores of HIVTSOs (at baseline) were not found to be associated with sociodemographic variables or the selected clinical indicators. When considering the 6month assessment (with blister package usage) with HIVTSQc, a significant positive satisfaction evolution was observed (also for the HIVTSQc subscale).

Table 2. Satisfaction (HIVTSQs and HIVTSQc scores) by sex, age group, education, nationality, and antiretroviral therapy duration

				Sex ²		A	Age group ²		1	Education ²		N	Nationality ²			Antiretroviral therapy duration ²		
	TOTAL	1	Female	Male		Less than 50 years	50 years or more		Secondary education or less	Superior education		Portuguese	Non- Portuguese		Up to 5 years	6 years or more		
	N = 105	\mathbf{p}^1	n = 22	n = 83	p^2	n = 69	n = 36	p^2	n = 66	n = 39	p^2	n = 59	n = 46	p^2	n = 55	n = 50	p ²	
HIVTSQs scale																		
Mean (SD)	54.69 (5.52)		55.05 (6.37)	54.59 (5.31)		54.83 (5.82)	54.42 (4.96)		54.64 (6.10)	54.77 (4.46)		53.90 (5.70)	55.70 (5.18)		54.25 (4.99)	55.16 (6.07)		
Median [Q1, Q3]	57.00 (51.00,	(a)	57.50 (53.50,	57.00 (51.00,	0.500	57.00 (51.00,	56.00 (51.00,	0.361	57.00 (50.25,	56.00 (51.00,	0.705	56.00 (50.00,	57.00 (54.00,	0.085	56.00 (50.00,	57.00 (53.25,	0.1	
	59.00)	(4)	59.75)	59.00)	0.500	60.00)	58.00)	0.501	59.00)	59.00)	0.702	59.00)	60.00)	0.002	59.00)	60.00)		
Minimum - Maximum	37.00 - 60.00		37.00 - 60.00	38.00 - 60.00		37.00 - 60.00	_ 42.00 - 60.00 _		37.00 - 60.00	47.00 - 60.00 _		37.00 - 60.00	38.00 - 60.00		43.00 - 60.00	37.00 - 60.00		
HIVTSQs General Satisfaction						*******										*******		
Mean (SD)	27.78 (2.61)		27.59 (2.84)	27.83 (2.56)		28.07 (2.48)	27.22 (2.78)		27.68 (2.81)	27.95 (2.25)		27.31 (2.81)	28.39 (2.20)		27.71 (2.38)	27.86 (2.86)		
Median [Q1, Q3]	29.00 (26.00, 30.00)	(a)	28.50 (24.75, 30.00)	29.00 (26.50, 30.00)	0.844	29.00 (27.00, 30.00)	28.00 (25.00, 30.00)	0.116	28.50 (27.00, 30.00)	29.00 (26.00, 30.00)	0.899	28.00 (25.00, 30.00)	29.00 (28.00, 30.00)	0.098	28.00 (27.00, 30.00)	29.50 (26.00, 30.00)	0.29	
Minimum - Maximum	20.00 - 30.00		22.00 - 30.00	20.00 - 30.00		20.00 - 30.00	21.00 - 30.00		20.00 - 30.00	23.00 - 30.00		21.00 - 30.00	20.00 - 30.00		23.00 - 30.00	20.00 - 30.00		
HIVTSQs Lifestyle/Ease subs									20.00 30.00			21.00 30.00	20.00 _ 50.00 _					
Mean (SD)	26.90 (3.52)		27.45 (4.07)	26.76 (3.37)		26.75 (3.76)	27.19 (3.03)		26.95 (3.86)	26.82 (2.88)		26.59 (3.37)	27.30 (3.69)		26.55 (3.33)	27.30 (3.70)		
` /	28.00 (25.00,		29.00 (28.00,	28.00 (25.00,		28.00 (25.00,	28.00 (25.00,		28.50 (25.00,	27.00 (25.00,		28.00 (25.00,	29.00 (26.25,		27.00 (25.00,	28.50 (27.00,		
Median [Q1, Q3]	30.00)	(a)	30.00)	30.00)	0.199	30.00)	30.00)	0.890	30.00)	30.00)	0.508	29.00)	30.00)	0.074	30.00)	30.00)	0.14	
Minimum - Maximum	15.00 - 30.00		15.00 - 30.00	17.00 - 30.00		15.00 - 30.00	20.00 - 30.00		15.00 - 30.00	20.00 - 30.00		15.00 - 30.00	17.00 - 30.00		17.00 - 30.00	15.00 - 30.00		
HIVTSQc scale																		
Mean (SD)	22.21 (9.14)		22.05 (10.27)	22.24 (8.93)		23.07 (7.96)	20.54 (10.99)		21.59 (9.00)	23.21 (9.40)		21.19 (10.23)	23.49 (7.46)		22.85 (8.06)	21.45 (10.31)		
Median [Q1, Q3]	25.50 (18.25,		26.00 (19.00,	25.00 (18.50,		26.00 (19.50,	25.00 (18.00,		25.00 (18.00,	28.00 (22.00,		25.00 (18.00,	26.00 (19.00,		26.00 (19.00,	25.00 (18.50,		
	29.00)	< 0.001	28.50)	29.00)	0.853	28.50)	29.00)	0.474	28.00)	29.50)	0.133	28.00)	29.00)	0.368	29.00)	28.00)	0.61	
Minimum - Maximum	-9 - 30		-6 - 30	-9 - 30		-6 - 30	-9 - 30		-6 - 30	-9 - 30		-9 - 30	0 - 30		0 - 30	-9 - 30		
(NA)	3		3	0		2	11		3	0		2	1		0	3		
HIVTSQc General Satisfaction																		
Mean (SD)	11.37 (4.74)		12.00 (5.11)	11.23 (4.67)		11.78 (4.21)	10.60 (5.60)		11.21 (4.65)	11.64 (4.93)		10.88 (5.10)	12.00 (4.20)		11.60 (3.99)	11.11 (5.52)		
Median [Q1, Q3]	13.00 (10.00,		14.00 (12.00,	13.00 (10.00,		13.00 (10.50,	12.00 (9.00,		12.00 (10.00,	14.00 (11.00,		12.00 (9.00,	14.00 (10.00,		13.00 (10.50,	14.00 (9.50,		
	15.00)	< 0.001	15.00)	15.00)	0.299	15.00)	15.00)	0.611	15.00)	15.00)	0.397	15.00)	15.00)	0.178	15.00)	15.00) -3 - 15	0.5	
Minimum - Maximum	-3 - 15		-3 - 15	-3 - 15		-3 - 15	-3 - 15		-3 - 15	-3 - 15		-3 - 15	0 - 15		0 - 15	-3 - 15		
(NA)	3		3	0		2	1		3	0		2	1		0	3		
HIVTSQc Lifestyle/Ease subs	scale																	
Mean (SD)	10.83 (4.97)		10.05 (6.11)	11.01 (4.69)		11.30 (4.53)	9.94 (5.68)		10.38 (4.96)	11.56 (4.96)		10.32 (5.35)	11.49 (4.41)		11.25 (4.33)	10.34 (5.63)		
Madian [01, 02]	13.00 (9.00,		13.00 (8.50,	13.00 (9.00,		13.00 (9.00,	12.00 (8.50,		12.00 (9.00,	14.00 (9.50,		12.00 (9.00,	13.00 (9.00,		13.00 (9.00,	12.00 (9.00,		
Median [Q1, Q3]	15.00)	< 0.001	14.00)	15.00)	0.621	15.00)	14.00)	0.262	14.00)	15.00)	0.094	15.00)	15.00)	0.375	15.00)	14.50)	0.50	
	-6 - 15		-3 - 15	-6 - 15		-3 - 15	-6 - 15		-3 - 15	-6 - 15		-6 - 15	-3 - 15		-2 - 15	-6 - 15		
Minimum - Maximum	3		3	0		2	1		3	0		2	1		0	3		

Table 3 also shows that satisfaction with a blister (measured with HIVTSQc) is not predicted by gender, age group, education level, nationality, or ART duration. On the other hand, an increase in the baseline treatment satisfaction score was associated with a decrease in the treatment satisfaction change score (six months after the switch to blister). For the HIVTSQc scale model, a one-unit increase in the baseline treatment satisfaction score (HIVTSQs) results in a decrease of 6% [exp (0.06)] in the HIVTSQc overall score.

203

204 205

206

207

208

209

210 Table 3. Satisfaction change (HIVTSQc scores): predictive effect of satisfaction at baseline (HIVTSQs), sociodemografic variables, 211 and clinical variables (linear models)

		Qc scale	HIVTSQc Gen	action / Clinical st	HIVTSQc Lifestyle/Ease subscale							
Model 1			Model 2	Model 1		Model 2		Model 1		Model 2		
	b (95% CI)	р	b (95% CI)	р	b (95% CI)	p	b (95% CI)	p	b (95% CI)	р	b (95% CI)	p
HIVTSQs*	-0.06 (-0.10; - 0.02)	0.002	-0.06 (-0.10; - 0.02)	0.003	-0.10 (-0.17; - 0.03)	0.006	-0.09 (-0.17; - 0.02)	0.016	-0.09 (-0.15; - 0.04)	0.001	-0.10 (-0.15; - 0.04)	<0.001
Sex												
Female	_		_		_		_		_		_	
Male	-0.03 (-0.56; 0.51)	0.926	0.08 (-0.47; 0.64)	0.769	0.27 (-0.20; 0.74)	0.252	0.29 (-0.20; 0.78)	0.240	-0.25 (-0.73; 0.23)	0.302	-0.14 (-0.64; 0.35)	0.559
Age group												
Less than 50 years	_		_		_		_		_		_	
50 years or more	0.12 (-0.32; 0.56)	0.591	0.03 (-0.44; 0.49)	0.913	0.02 (-0.37; 0.41)	0.918	0.02 (-0.39; 0.44)	0.914	0.26 (-0.12; 0.65)	0.178	0.17 (-0.23; 0.57)	0.409
Education												
Secondary education or less	_		_		_		_		_		_	
Superior education	-0.34 (-0.76; 0.08)	0.114	-0.31 (-0.76; 0.15)	0.183	-0.13 (-0.51; 0.25)	0.498	-0.17 (-0.57; 0.23)	0.390	-0.36 (-0.73; 0.01)	0.060	-0.27 (-0.67; 0.12)	0.174
Nationality												
Portuguese	_		_		_		_		_		_	
Non-Portuguese	-0.10 (-0.52; 0.33)	0.655	-0.07 (-0.50; 0.35)	0.735	-0.16 (-0.54; 0.21)	0.388	-0.16 (-0.54; 0.23)	0.420	-0.15 (-0.52; 0.23)	0.435	-0.11 (-0.49; 0.26)	0.549
Antiretroviral therapy duration												
Up to 5 years	_		_		_		_		_		_	
6 years or more	0.21 (-0.21; 0.62)	0.331	0.14 (-0.31; 0.59)	0.541	-0.08 (-0.45; 0.29)	0.670	-0.08 (-0.48; 0.32)	0.705	0.24 (-0.13; 0.61)	0.207	0.11 (-0.28; 0.51)	0.574

^{*} These coefficients report to scores in HIVTSQs scale, HIVTSQs General Satisfaction / Clinical subscale and HIVTSQs Lifestyle/Ease subscale in models for HIVTSQc scale, HIVTSQc General Satisfaction / Clinical subscale and HIVTSQc Lifestyle/Ease subscale, respectively. For analysis, HIVTSQc scores were shifted, reversed and log transformed. Model 1, Individual models adjusted for each variable presented, plus the HIVTSQs score

Model 2, Model adjusted for all the variables presented

218 This predictive value of baseline satisfaction (HIVTSQs) was also observed for the 219 HIVTSOc subscale (general satisfaction/clinical subscale).

Plots in Figure 2 provide some insight into the facets of blister packaging, as perceived by patients (compared with bottles) that may support the observed positive evolution of satisfaction. Although no significant difference was found in the proportion of patients reporting appreciating positively the packaging (bottle and blister), three main facets of usage were found to be better considered by patients: a significantly higher proportion of them considered that the blister helps them to keep track of daily intake of pills; a higher proportion indicate that blister packaging usage is more discrete than bottle usage; and a higher proportion report that blister packaging helps them to recall the refill momentum.

Figure 3. Frequencies of item response on the specifically developed questionnaire between packaging methods

Overall, and as seen in Figure 3, 68.6% of patients report being more satisfied with the blister packaging than with bottle packaging.

Figure 4. Response distribution on patients' satisfaction with blister packaging, when compared with bottle packaging

Regarding adherence, no significant differences were observed between the standard pill bottle and monthly blister packaging: 89.7% and 91.3% of adherence, respectively.

Discussion

220

221

222

223

224

225

226

227

228 229

230

231 232

233

234 235

236

237 238

239

240

241 242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

Main aim of this project was to assess if introducing a new packaging would affect satisfaction and adherence with ART. The study was planned as a two-center, observational retrospective and prospective study with 18+ years old PLHIV conducted in Portuguese hospitals (non-random sampling). The bottle effect was assessed retrospectively for at least six months, and the blister effect was prospectively evaluated for a period of at least six months of usage. Overall, 105 PLHIV were enrolled and 102 completed the prospective component of the study.

The main outcome of the study was satisfaction with ART treatment. Patients reported an increase in satisfaction with the Biktarvy® blister packaging (compared with previous bottle packaging). And this increase in satisfaction was independent of several main sociodemographic and clinical characteristics. Importantly, the patients who became more satisfied with ART treatment (when using blister packaging) were the least satisfied with bottle packaging.

Another main finding regards the perception of utility from the blister packaging: after a minimum of six month of experience, the blister (which includes a weekly calendar) was considered by the majority (85%) of patients as an effective tool to keep track of their daily intake of pills (significant higher percentage than the appreciation for bottle packaging), and about two third of patients considered that it is helpful as a reminder of the adequate moment of refilling.

Conclusion

To our knowledge this is the first study evaluating satisfaction with blister calendar package usage of ART by PLHIV, and the same for medication packaging in blister packs with a weekly calendar for the treatment of different diseases. Overall, these findings support the advantages of the new packaging. Nevertheless, adherence was not found to be significantly higher for blister than for bottle packaging (though with a slight increase of proportion in adherence: 1.6 percentual points). This issue calls for future research, also because the lapse of time after introducing the new packaging was limited (about six months). Larger samples, including selected populations with more extended periods of blister utilization, may provide sounder evidence about the adherence potential of this Biktarvy® new packaging.

263

264

265 266

267

268

269

270

271

272

Acknowledgments

273

274

278

279 280

281

282

283

296

297 298 299

300

301

302

303

304

305

306

307

308

309

310 311

312

313

314

315

316

The authors thank the patients who accepted to participate in the study, Prof. Clare Bradley 275 276 and Health Psychology Research Limited (HPR) for the HIVTSQs and HIVTSQc, and Ana 277

Sequeira and Hugo Caldeira for technical assistance.

Conflict of interests

The authors declare no conflict of interest, except for Maria Pinto da Silva who is an employee of Gilead Sciences, Lda., Lisboa, Portugal, and owns shares in Gilead.

Supporting information captions

- 284 Figure 1. Study design diagram
- 285 Table 1. Sociodemographic and clinical characteristics of the participants
- 286 Figure 2. HIVTSQs (and subscales) and HIVTSQc total scores correlations (Spearman 287 correlation)
- 288 Table 2. Satisfaction (HIVTSQs and HIVTSQc scores) by sex, age group, education,
- 289 nationality, and antiretroviral therapy duration
- 290 Table 3. Satisfaction change (HIVTSQc scores): predictive effect of satisfaction at baseline
- 291 (HIVTSQs), sociodemografic variables, and clinical variables (linear models)
- 292 Figure 3. Frequencies of item response on the specifically developed questionnaire between 293 packaging methods
- 294 Figure 4. Response distribution on patients' satisfaction with blister packaging, when 295 compared with bottle packaging

References

- 1. EACS Guidelines version 12.0, October 2023.
- 2. Paramesha AE, Chacko LK. Predictors of adherence to antiretroviral therapy among PLHIV. Indian J Public Health. 2019;63(4):367-76.
- 3. Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, Quirk E. Patientreported symptoms over 48 weeks among participants in randomized, double-blind, phase III non- inferiority trials of adults with HIV on co-formulated bictegravir. emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11(5):561-73.
- 4. Curran A, Arends J, Buhk T, Cascio M, Teofilo E, van den Berk G, Guaraldi G. "Moving Fourth": Introduction of a practical toolkit for shared decision-making to facilitate healthy living beyond HIV viral suppression. AIDS Rev. 2021;23(4):204-
- 5. Schneider PJ, Murphy JE, Pedersen CA. Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc (2003). 2008;48(1):58-63.
- 6. Conn VS, Ruppar TM, Chan KC, Dunbar-Jacob J, Pepper GA, De Geest S. Packaging interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res Opin. 2015;31(1):145-60.

- 317 7. Biktarvy Summary of Product Characteristics, May 2021.
- 318 8. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment 319 Satisfaction Questionnaire status version and new change version. Value Health. 320 2006;9(5): 320-33.
- Serrão R, Mansinho K, Maltez F, Marques N, Carvalho A, Pazos R, et al. Real-321 322 World characterization of the portuguese population living with HIV who initiated 323 raltegravir based-regimens: The REALITY Study. Acta Med Port. 2022;35(7-324 8):558-65.

Delivery of Biktarvy® bottles	First delivery of Biktarvy® monthly blisters		Later delivery of Biktarvy® monthly blisters
Retrospective assessment for satisfaction: Biktarvy® bottle for at least 6 months		Prospective assessment for satisfaction: Biktarvy® blister for at least 6 months	
Pharmacy records collected on adherence: Total tablets (= prior + deliver remaining) Total days since last pick-up	red –	Pharmacy records collected on adherence: Total tablets (= prior + delivered - remaining) Total days since last pick-up	
	Time 0: participants fill in HIVTSQs		Time 1: participants fill in HIVTSQc

Figure 1




Figure 2




Figure 3

I am more satisfied with this packaging than with the previous one




Figure 4